Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 6, 2008, Pages 674-678

  Kennedy, M J ^a   Davis, D A ^a   Smith, N ^a   Gaedigk, A ^b,c   Pearce, R E ^b,c   Kearns, G L ^b,c  

^a University of Louisville School of Medicine   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DNA; DRUG METABOLITE; GROWTH HORMONE; XANTHINE OXIDASE;

ADOLESCENT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENOTYPE; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HUMAN; MALE; PHENOTYPE; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCHOOL CHILD; URINALYSIS;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; ENZYME ACTIVATION; FEMALE; GENOTYPE; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; MALE; PROBABILITY; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; XANTHINE OXIDASE;

EID: 56549100592     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.185     Document Type: Article

References (30)

1. Waxman, D.J. & O'Connor, C. Growth hormone regulation of sex-dependent liver gene expression. Mol. Endocrinol. 20, 2613-2629 (2006).
2. Cheung, N.W., Liddle, C., Coverdale, S., Lou, J.C. & Boyages, S.C. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. J. Clin. Endocrinol. Metab. 81, 1999-2001 (1996).
3. Redmond, G.P., Bell, J.J., Nichola, P.S. & Perel, J.M. Effect of growth hormone on human drug metabolism: time course and substrate specificity. Pediatr. Pharmacol. (New York) 1, 63-70 (1980).
4. Redmond, G.P., Bell, J.J. & Perel, J.M. Effect of human growth hormone on amobarbital metabolism in children. Clin. Pharmacol. Ther. 24, 213-218 (1978).
5. Rifkind, A.B., Saenger, P., Levine, L.S., Pareira, J. & New, M.I. Effects of growth hormone on antipyrine kinetics in children. Clin. Pharmacol. Ther. 30, 127-132 (1981).
6. Lindsay, R., Feldkamp, M., Harris, D., Robertson, J. & Rallison, M. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J. Pediatr. 125, 29-35 (1994).
7. Kennedy, M.J., Abdel-Rahman, S.M., Kashuba, A.D. & Leeder, J.S. Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J. Clin. Pharmacol. 44, 708-714 (2004).
8. Kennedy, M.J., Scripture, C.D., Kashuba, A.D., Scott, C.S., Gaedigk, A. & Kearns, G.L. Activities of cytochrome P450 1A2, N-acetyltransferase 2, xanthine oxidase, and cytochrome P450 2D6 are unaltered in children with cystic fibrosis. Clin. Pharmacol. Ther. 75, 163-171 (2004).
9. Matzke, G.R., Frye, R.F., Early, J.J., Straka, R.J. & Carson, S.W. Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy 20, 182-190 (2000).
10. Saenger, P., Rifkind, A.B. & New, M.I. Changes in drug metabolism in children with thyroid disorders. J. Clin. Endocrinol. Metab. 42, 155-159 (1976).
11. Kotlyar, M. & Carson, S.W. Effects of obesity on the cytochrome P450 enzyme system. Int. J. Clin. Pharmacol. Ther. 37, 8-19 (1999).
12. Li, R.S. et al. Growth hormone inhibits the 11 beta-hydroxysteroid dehydrogenase type 1 gene promoter activity via insulin-like growth factor I in HepG2 cells. Horm. Metab. Res. 40, 286-288 (2008).
13. Kashuba, A.D. et al. Quantification of intraindividual variability and the influence of menstrual cycle phase on CYP2D6 activity as measured by dextromethorphan phenotyping. Pharmacogenetics 8, 403-410 (1998).
14. Rost, K.L. & Roots, I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin. Pharmacol. Ther. 55, 402-411 (1994).
15. Kashuba, A.D. et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin. Pharmacol. Ther. 63, 540-551 (1998).
16. Ellis, E.F., Koysooko, R. & Levy, G. Pharmacokinetics of theophylline in children with asthma. Pediatrics 58, 542-547 (1976).
17. Rey, E. et al. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam. Clin. Pharmacol. 15, 355-359 (2001).
18. Darendeliler, F., Hindmarsh, P.C., Preece, M.A., Cox, L. & Brook, C.G. Growth hormone increases rate of pubertal maturation. Acta Endocrinol. (Copenh.) 122, 414-416 (1990).
19. Wilson, T.A. et al. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. J. Pediatr. 143, 415-421 (2003).
20. Balis, F.M. et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin. Pharmacol. Ther. 41, 384-387 (1987).
21. Michalets, E.L. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18, 84-112 (1998).
22. Pacher, P., Nivorozhkin, A. & Szabo, C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol. Rev. 58, 87-114 (2006).
23. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J. & Leeder, J.S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234-242 (2008).
24. Kennedy, M.J., Davis, D.A., Smith, N.B., Gaedigk, A., Pearce, R.E. & Kearns, G.L. Six-month, prospective, longitudinal, open-label caffeine and dextromethorphan phenotyping study in children with growth hormone deficiency receiving recombinant human growth hormone (rhGH) replacement. Clin. Ther. 30, 1687-1699 (2008).
25. Grant, D.M., Tang, B.K. & Kalow, W. A simple test for acetylator phenotype using caffeine. Br. J. Clin. Pharmacol. 17, 459-464 (1984).
26. Blake, M.J. et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin. Pharmacol. Ther. 81, 510-516 (2007).
27. Campbell, M.E., Spielberg, S.P. & Kalow, W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin. Pharmacol. Ther. 42, 157-165 (1987).
28. Grant, D.M., Tang, B.K., Campbell, M.E. & Kalow, W. Effect of allopurinol on caffeine disposition in man. Br. J. Clin. Pharmacol. 21, 454-458 (1986).
29. Tang, B.K., Kadar, D., Qian, L., Iriah, J., Yip, J. & Kalow, W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin. Pharmacol. Ther. 49, 648-657 (1991).
30. Schmid, B., Bircher, J., Preisig, R. & Kupfer, A. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin. Pharmacol. Ther. 38, 618-624 (1985).